Company / EPS (Diluted)
Editas Medicine, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.88
FY2025
5-year range
-$3.21 / -$1.98
FY2021-FY2025
Trend
+10.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-2.88.
Based on SEC 10-K filings.
-2.88 in FY2025.
Remained stable around $-2.88 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 10.3% year-over-year.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.88 | +10.3% |
| FY2024 | -$3.21 | -12.6% |
| FY2023 | -$2.85 | -43.9% |
| FY2022 | -$1.98 | +26.1% |
| FY2021 | -$2.68 | -2333.3% |
| FY2020 | $0.12 | +104.0% |
| FY2019 | -$2.98 | +1.3% |
| FY2018 | -$3.02 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026